Candel Therapeutics, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
CADL
Candel Therapeutics, Inc. Common Stock
$13.13 +6.32%
VS HALOHalozyme Therapeutics, Inc.
$108.17 +1.93%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| CADL | HALO | |
|---|---|---|
| Market Cap | $1.00 billion | $12.28 billion |
| Revenue (TTM) | — | $1.66 billion |
| Net Income (TTM) | $-88,531,000 | $413.60 million |
HALO leads on 3 of 3 size & scale factors.
Valuation
| CADL | HALO | |
|---|---|---|
| P/E Ratio | — | 31.54 |
| Price / Book | 7.97 | 85.53 |
| Price / Sales | — | 7.38 |
CADL leads on 1 of 1 valuation factors.
Profitability
| CADL | HALO | |
|---|---|---|
| Net Margin | — | 24.86% |
| Return on Equity | -70.19% | 288.13% |
HALO leads on 1 of 1 profitability factors.
Risk & Sentiment
| CADL | HALO | |
|---|---|---|
| Short Interest | 0.04% | 9.79% |
CADL leads on 1 of 1 risk & sentiment factors.
Dig deeper: CADL overview, CADL financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.